Xufeng Guo

Comparison of perioperative outcomes between open and minimally invasive esophagectomy for esophageal cancer.

To compare surgical outcomes of thoracoscopic and laparoscopic esophagectomy with open esophagectomy in order to study the learning curve of minimally invasive surgery for esophageal cancers.

Clinical study on postoperative recurrence in patients with pN0 esophageal squamous cell carcinoma

BackgroundDespite increasingly radical surgery for esophageal carcinoma, many patients still develop tumor recurrence after operation. This study was designed to analyze the clinical and pathologic influencing factors of early recurrence in patients with histological node-negative (pN0 stage) esophageal squamous cell carcinoma (ESCC) after radical esophagectomy.MethodsA retrospective study on 112 consecutive pN0 stage ESCC patients who underwent esophagectomy with lymphadenectomy by the same surgical team from January 2004 to December 2010. There were 92 male and 20 female patients, aging from 36 to 80 years with a mean age of 60.3 years. The Cox proportional hazards model was used to determine the independent risk factors for recurrence within 3 years after the operation.ResultsRecurrence was recognized in 45 patients (40.2%) within 3 years after operation. The median time to tumor recurrence was 17.4 months. Locoregional recurrence was found in 38 patients (33.9%) and hematogenous metastasis in 7 patients (6.3%). However, locoregional recurrence accounted for 84.4% of all relapse patients. Recurrence closely correlated with tumor location, grade of differentiation, primary tumor stage (pT) and pathologic stage (χ2 = 6.380 to 18.837, p < 0.05). The Cox multivariate analysis showed that upper/middle thoracic location (OR = 1.092, p = 0.049) and pT3-4a stage (OR = 3.296, p = 0.017) were independent risk factors for postoperative locoregional recurrence.ConclusionLocoregional recurrence was the most common recurrence pattern of patients with pN0 ESCC within 3 years after operation. Upper/middle thoracic location and pT3-4a stage were independent risk factors for locoregional recurrence of pN0 ESCC after radical esophagectomy.

Comparison of complete and minimal mediastinal lymph node dissection for non‐small cell lung cancer: Results of a prospective randomized trial

To compare surgical results, pathological staging, and survival between complete and minimal mediastinal lymph node dissection for non‐small cell lung cancer (NSCLC).

Adenoid cystic carcinoma of the esophagus: report of two cases and review of the Chinese literature

Squamous cell carcinoma is the major pathology type of esophageal cancer in China, where adenocarcinoma is rare and adenoid cystic carcinoma (ACC) is more rare comparing to the western countries. We report the surgical and pathologic findings of two cases of primary ACC of the esophagus, and review of the Chinese literature of this tumor.Virtual slidesThe virtual slide(s) for this article can be found here: http://www.diagnosticpathology.diagnomx.eu/vs/1507582238843246

Clinical study on postoperative recurrence in patients with pN1 esophageal squamous cell carcinoma.

The 7th edition Union for International Cancer Control esophageal cancer staging system has changed the pathological N stage from N0, N1 (the existence state of regional lymph node metastasis) to N0, N1, N2, and N3 (number of regional lymph node metastasis). This study was designed to analyze the influencing factors of early recurrence in patients with pathological N1 stage (pN1 stage) esophageal squamous cell carcinoma (ESCC) after radical esophagectomy.

Impact of unplanned events on early postoperative results of minimally invasive esophagectomy

Minimally invasive esophagectomy (MIE) is increasingly performed worldwide. Unplanned events during thoracoscopy or laparoscopy can jeopardize the procedure, sometimes necessitating conversion to open surgery. The aim of this study was to evaluate the impact of unplanned events on early postoperative outcomes after MIE.

Adjuvant radiotherapy, chemotherapy or surgery alone for high-risk histological node negative esophageal squamous cell carcinoma: Protocol for a multicenter prospective randomized controlled trial: Adjuvant therapy for esophageal cancer

Histologically node negative esophageal squamous cell carcinoma (pN0 ESCC) after radical resection still carries a significant risk of recurrence, especially in high‐risk patients. Our previous study showed that the risk of recurrence was associated with tumor location and cell differentiation, as well as the presence of lymphovascular invasion. Most recurrence occurs within two years after surgery. There is still a lack of knowledge on the risks or potential benefits of postoperative adjuvant therapies for high‐risk pN0 ESCC patients. This study was designed to evaluate the efficacy and toxicity of adjuvant therapies after radical surgery in high‐risk patients with pN0 ESCC. This study is a multicenter, prospective, controlled randomized trial, which will compare the differences between either adjuvant chemotherapy or adjuvant radiotherapy and surgery alone for high‐risk pN0 ESCC. Patients in group A will receive three cycles of adjuvant chemotherapy with paclitaxel and cisplatin, patients in group B will receive adjuvant radiotherapy with intensity‐modulated radiation of 50 Gy, and patients in group C (the control) will receive surgery alone. The primary endpoint is three‐year disease‐free survival. Secondary endpoints include toxicity of adjuvant therapies and five‐year overall survival. One hundred and sixty‐two patients in each group are required and a total of 486 patients will finally be enrolled into the study. This will be the first randomized trial to investigate the necessity or potential benefit of postoperative adjuvant therapies for high‐risk pN0 ESCC patients.

ERAS prior to minimally invasive esophagectomy

The concept and pattern of enhanced recovery after surgery (ERAS) have been used for nearly 20 years. However, the clinical application and popularization of ERAS in the esophagectomy have been greatly restricted due to the complexity of operation and the high incidence of postoperative complications. In recent years, with the growing maturity of the minimally invasive technique of thoracic laparoscopy, the attention of the concept of tissue and organ protection, the improvement of making gastric tube and the presentation and application of new concepts, ERAS has made a breakthrough in the field of esophagectomy. In this paper, the ERAS clinical pathway prior to minimally invasive esophagectomy (MIE) of Shanghai chest hospital was summarized, including preoperative preparation and evaluation, preoperative education and so on. The aim is to continuously improve and popularize the clinical pathway of ERAS in MIE, applying in more and more centers, so as to benefit more and more patients.

Evaluation and patient selection for minimally invasive esophagectomy

Minimally invasive esophagectomy (MIE) is an evolving surgical alternative to traditional open esophagectomy. Despite considerable technical challenges, it was considered that MIE could be performed effectively by surgeons experienced in open esophageal resection and advanced laparoscopic surgery. This chapter illustrates the preoperative evaluation and operative indications of MIE for esophageal cancer. Firstly, a complete history and physical exam is required for counseling on preoperative optimization. Then, the operation can be conducted after standard preoperative work-up includes several parts, such as positron-emission tomography (PET), endoscopic ultrasound (EUS), esophagography and computed tomography (CT). To our knowledge, the operative indications for MIE is now extended due to the rapid development of surgical technique and detailed preoperative evaluation. Limited node invasion and neoadjuvant chemoradiation are not rigorous contraindications for MIE any more. Optimal results require elaborate evaluation, appropriate patient selection and a multidisciplinary team experienced in the management of esophageal cancer.

The era of minimally invasive esophagectomy

Minimally Invasive Esophagectomy (MIE) has become a standard surgical approach for esophageal cancer in the world. In this report, we introduce the history of MIE which is different between eastern and western countries. With the development of surgical techniques, including single-lumen endotracheal intubation, CO2 artificial pneumothorax, and surgical positioning, the MIE has made great progress. It was approved that due to significantly reduced surgical trauma, MIE lowers postoperative morbidity and mortality while achieving a tumor resection efficacy comparable with the conventional open esophagectomy. The improvement of surgical instruments and modification of surgical approaches are the keys to gaining greater clinical advantage in the future of MIE, especially the popularity of robotic surgery.